Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months. The drug, now under regulatory review, was greeted as a breakthrough, the closest thing the field has ever had to a vaccine.

On Tuesday, Gilead published early data suggesting a new formulation of the drug  could be used to prevent infection with just a single shot every year. 

Read the rest…